alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Product Information 

 

DOW CONFIDENTIAL - Do not share without permission 

Unrestrited – May be shared with anyone ®TMTrademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow Form No. 119-02220 

Page 1 of 2 Dow Surfactants 

ECOSURFTM LF-30 

Product Information 

Chemical 

Description 

Name: Secondary Alcohol Alkoxylate 

Surfactant Type: Nonionic 

Benefits  Superior wetting 

 Low Foam 

 Excellent Caustic Stability 

 APE Free 

 Outstanding formulation & handling 

properties 

 Readily biodegradable (OECD 301) 

 Low Aquatic Toxicity 

Applications  Paints & coatings 

 High performance cleaners 

 Foam Control 

 Hard surface cleaners 

 Pulp & paper 

 Textiles 

 Oilfield 

 Agrochemicals 

Typical Physical Properties 

Cloud Point (1) 33 

HLB (2) 11 - 12 

Polydispersity 1.07 

CMC(3) / Surface Tension(4) 26 / 30 

Foam Height(5) 60 / 5 

Pour Point(6) -5°C 

Form(7) Pale yellow liquid 

pH, 1% aq solution 7.0 

Viscosity at 40°C (104°F), cSt 36.096 

Density at 40°C (104°F), g/mL 0.9836 

Flash Pt, Closed Cup, ASTM D93 193°C 380°F (est) 

(1) Cloud point: °C, 1% Aqueous, (2) HLR Range: <10 w/o emulsifier, > 10 o/w emulsifier, (3) Critical micelle concentration: ppm at 25°C, (4) Surface tension: dynes/cm at 

0.2% actives, 25°C, (5) Ross-Miles foam height: mm at 0.1 wt% actives, (6) Pour point: °C, (7) Form at 25°C 

Solubility and 

Compatibility 

 Dispersible in water 

 Soluble in chlorinated solvents and most polar organic solvents 

 Chemically stable in the presence of dilute acids, bases and salts 

 Compatible with anionic , cationic, and other nonionic surfactants 

Disposal Although the ECOSURFTM LF Surfactants are considered readily biodegradable (>60 

percent biodegradation within 28 days per OECD 301F) it has been determined that for 

unused & contaminated product, the preferred option for disposal is via a licensed, permitted 

incinerator or other thermal destruction device. These efforts to minimize emissions to the 

environment are consistent with Dow’s overall commitment to the Responsible Care® 

Guiding Principles. 

Contact information: 

North America: 1-800-477-4369 

Europe: (+32) 3-450-2240 

Asia/Pacific: (+852) 2879 7339 

Other areas: 1-989-832-1556 

http://www.dow.com/surfactants 

NOTICE: No freedom from any patent owned by Seller or others is to be inferred. Because use conditions and applicable laws 

may differ from one location to another and may change with time, Customer is responsible for determining whether products 

and the information in this document are appropriate for Customer’s use and for ensuring that Customer’s workplace and 

disposal practices are in compliance with applicable laws and other governmental enactments. Seller assumes no obligation or 

liability for the information in this document. NO WARRANTIES ARE GIVEN; ALL IMPLIED WARRANTIES OF 

MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AREEXPRESSLY EXCLUDED. 
DOW CONFIDENTIAL - Do not share without permission 

 – May be shared with anyone ®TMTrademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow Form No. 119-02220 

Page 2 of 2 Dow Surfactants
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1

IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF CALIFORNIA

MATTHEW B. CRAMER, ET AL., No. CIV-S-04-2441 MCE/GGH P

Plaintiff, 

v. ORDER

STATE OF CALIFORNIA, ET AL., 

Defendants.

 /

Plaintiff, a state prisoner proceeding pro se, has filed

this civil rights action seeking relief under 42 U.S.C. § 1983. 

The matter was referred to a United States Magistrate Judge

pursuant to 28 U.S.C. § 636(b)(1)(B) and Local General Order No.

262.

On June 10, 2005, the magistrate judge filed findings and

recommendations herein which were served on plaintiff and which

contained notice to plaintiff that any objections to the findings

and recommendations were to be filed within twenty days.

///

Case 2:04-cv-02441-MCE -GGH Document 14 Filed 09/01/05 Page 1 of 2
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

2

Plaintiff has not filed objections to the findings and

recommendations.

Although it appears from the file that plaintiff’s copy of

the findings and recommendations was returned, plaintiff was

properly served. It is the plaintiff’s responsibility to keep

the court apprised of his current address at all times. Pursuant

to Local Rule 83-182(f), service of documents at the record

address of the party is fully effective.

The court has reviewed the file and finds the findings and

recommendations to be supported by the record and by the

magistrate judge’s analysis. Accordingly, IT IS HEREBY ORDERED

that:

1. The findings and recommendations filed June 10, 2005,

are adopted in full; and

2. This action is dismissed without prejudice. See Local

Rule 11-110; Fed. R. Civ. P. 41(b).

DATE: September 1, 2005 

_____________________________

MORRISON C. ENGLAND, JR

UNITED STATES DISTRICT JUDGE

Case 2:04-cv-02441-MCE -GGH Document 14 Filed 09/01/05 Page 2 of 2
Exhibit 10.23.1

ALLOS THERAPEUTICS, INC.

FIRST AMENDMENT TO
EMPLOYMENT AGREEMENT

MICHAEL E. SCHICK

ThisFIRST AMENDMENT TO EMPLOYMENT AGREEMENT(this "First
Amendment") is entered into effective as of March 2, 2011, by and betweenALLOS THERAPEUTICS, INC.(the
"Company") andMICHAEL E. SCHICK("Employee")
(collectively, the "Parties").

RECITALS:

WHEREAS, the Parties entered into an Employment Agreement on September 16, 2010 (the
"Employment Agreement");

WHEREAS, modifications are needed to bring the Employment Agreement into compliance with Section 409A of the Internal Revenue Code
of 1986, as amended.

NOW, THEREFORE, in consideration of the promises, mutual covenants, the above recitals, and the agreements herein set forth, and for other
good and valuable consideration, the sufficiency of which is hereby acknowledged, the Company and Employee hereby agree as follows:







1

---





[Signature Page Follows]

2

---



IN WITNESS WHEREOF,the parties hereto have each duly executed thisFIRST AMENDMENT TO EMPLOYMENT
AGREEMENTeffective as of the date and year first written above.

ALLOS THERAPEUTICS, INC.By:

/s/ Paul L. BernsName:

Paul L. BernsTitle:

President and Chief Executive OfficerEMPLOYEE:/s/ Michael E. Schick MICHAEL E. SCHICK


Signature Page to First Amendment to
Employment Agreement

3

---



QuickLinks
Avg       Avg Common
                               Common      & Dilutive     Basic    Dilutive
     Year      Net Income    Shares O/S    Shares O/S      EPS       EPS
     ----      ----------    ----------    ----------      ---       ---

     1999       $148,016      2,005,158     2,086,505     $0.07     $0.07

     1998         13,771      2,005,121     2,046,813      0.01      0.01

     1997         46,386      2,002,343     2,006,777      0.02      0.02